Chronic inflammation of the brain is a known pathophysiological hallmark of various neurodegenerative diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), and Parkinson's disease (PD), all demonstrated in animal models to benefit from GLP-1 mimetics therapy (14, 26, 30). This evidence concerns the gene GLP1R and Parkinson disease.